Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Study Summary

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Conditions

Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)

Interventions / Drugs

Miricorilant

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment8 participants

Primary Completion—

Lead SponsorCorcept Therapeutics

Data Retrieved2026-04-11 04:10:22.666705+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.